Novo Nordisk, obesity and CagriSema

Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results
New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an earlier study recorded 22.7%.
CagriSema demonstrates superior weight loss in adults with obesity, type 2 diabetes in REDEFINE 2 trial: Novo Nordisk
Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial, Novo Nordisk said in a release.The headline results
Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Novo Nordisk Shares Sink on Latest CagriSema Weight Loss Drug Study
Key Takeaways Novo Nordisk's U.S.-listed shares fell Monday after it released the latest results for its developmental weight loss drug CagriSema.The average weight loss among those taking the new drug was 15.
Novo Nordisk (NVO) Sinks after Weight-Loss Drug Trial Misses Expectations
Shares of Novo Nordisk’s (NVO) are down over 9% at the time of writing after the company announced the results from its latest weight-loss drug
Data on new Novo Nordisk obesity drug disappoints in trial, stirs worries Lilly gaining edge in sector
Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over Novo in the weight-loss drugs market.
Clinical Pain Advisor4h
REDEFINE 2: Significant Weight Loss Observed With CagriSema vs Placebo in Patients With T2D
Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
Endocrinology Advisor2d
Significant Weight Loss Observed With CagriSema in REDEFINE 2 Trial
Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
Novo Nordisk: CagriSema Disappoints Again
Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...
Healio4d
CagriSema confers 15.7% weight loss at 68 weeks for adults with obesity, type 2 diabetes
Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...
Novo Nordisk reports REDEFINE 2 trial of CagriSema achieved primary endpoint
Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy ...
Novo Nordisk: Stock Plunges, But It May Be Time To Load Up
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
BI Weekend: Oracle, Kohl’s Earnings, CERAWeek
Alix Steel and Paul Sweeney harness the power of Bloomberg Intelligence to analyze market news and provide in-depth company and industry research.
GlobalData on MSN4d
Novo Nordisk’s stock drops despite CagriSema hitting goal of Phase III trial
The Wegovy successor was able to meet its primary endpoint with a 15.7% weight loss among those dosed with the combination ...
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...